Full Text View
Tabular View
No Study Results Posted
Related Studies
Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh
This study is currently recruiting participants.
Study NCT00198822   Information provided by Johns Hopkins Bloomberg School of Public Health
First Received: September 12, 2005   Last Updated: September 6, 2006   History of Changes

September 12, 2005
September 6, 2006
August 2001
 
  • All-cause pregnancy-related maternal mortality
  • Perinatal and neonatal mortality
  • Three-month infant mortality
Same as current
Complete list of historical versions of study NCT00198822 on ClinicalTrials.gov Archive Site
  • Maternal morbidity, including obstetric complications
  • Gestational age at birth
  • Fetal and postnatal growth through three months of age
  • Infant morbidity through three months of age
  • Maternal and infant nutritional status
Same as current
 
Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh
Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh

The purpose of this trial is to determine whether providing women with a weekly oral supplement of vitamin A, either preformed or as beta-carotene, at a dosage equivalent to a recommended intake from early pregnancy through three months postpartum, can reduce the risk of maternal mortality, fetal loss, or infant mortality.

Maternal mortality and vitamin A deficiency coexist in rural South Asia. In Nepal, weekly supplementation with vitamin A or beta-carotene during the child-bearing years reduced all-cause maternal mortality and, in night blind women, also infant mortality. The present trial is testing the efficacy of the same supplements from ~9 weeks' gestation to 12 weeks postpartum. The planned sample size is 68,000 pregnancies. It is being conducted in 19 rural unions, covering an area of ~750 sq km with a population of ~580,000 in Gaibandha and Southern Rangpur Districts in Northern Bangladesh. The study area was mapped as 596 "sectors" (unit of randomization), each comprising 200-275 households; ~135,000 houses were numerically addressed and, at the outset, 103,000 women were listed. Women are visited at home every 5 weeks by 596 trained female staff to detect pregnancy by a combination of menstrual history and urine testing. Newly married women are prospectively enlisted for pregnancy surveillance. Following informed consent urine-positive (pregnant) women detected during surveillance are enrolled to receive weekly a capsule containing 7000 retinol equivalents of preformed vitamin A, 42 mg of beta-carotene or placebo. Vital events are recorded weekly through 3 months postpartum. Trained interviewers conduct maternal nutritional and health and household socioeconomic assessments in the 1st trimester. At 3 months postpartum, interviewers assess both mother and infant for health and nutritional status, including apparent birth defects that are later physician-confirmed. An additional home health assessment occurs at 6 months post partum, and vital status is recorded for mother and infant at one year postpartum. A ~3% subsample of enrolled pregnant women participate in a substudy involving enhanced clinical, anthropometric, biochemical, body compositional, morbidity and interview-based assessment protocols in the 1st, 2nd and 3rd trimesters, and at 3 months post-partum. Reported maternal and infant deaths are verified and causes ascertained during "verbal autopsy" interviews with family members of the deceased.

Phase III
Interventional
Prevention, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study
Vitamin A Deficiency
Drug: Vitamin A or Beta-Carotene Supplements
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
68000
May 2007
 

Inclusion Criteria:

  • Married women of reproductive age
  • First pregnancy during time period of trial

Exclusion Criteria:

  • Premenarchial girls
  • Married women with a previous pregnancy enrolled into the trial
  • Previously married women who have moved into the study area
  • Single women (never married, widowers)
  • Women who are sterilized (or whose husbands are sterilized)
  • Menopausal women
Female
15 Years to 49 Years
Yes
Contact: Keith P West, Jr., Dr.P.H. 410-955-2061 kwest@jhsph.edu
Contact: Parul Christian, Dr.P.H. 410-955-1188 pchristi@jhsph.edu
Bangladesh
 
NCT00198822
 
GHS-A-00-03-00019-00
Johns Hopkins Bloomberg School of Public Health
  • United States Agency for International Development (USAID)
  • Bill and Melinda Gates Foundation
  • The Canadian International Development Agency
  • The Sight and Life Research Institute
  • Access Business Group
Principal Investigator: Keith P West, Jr., Dr.P.H. Johns Hopkins Bloomberg School of Public Health
Study Director: Parul Christian, Dr.P.H. Johns Hopkins Bloomberg School of Public Health
Study Director: Rolf DW Klemm, Dr.P.H. Johns Hopkins Bloomberg School of Public Health
Study Director: Mahbubur Rashid, MBBS, MSc JiVitA Bangladesh Project
Study Director: Alain B Labrique, MSc Johns Hopkins Bloomberg School of Public Health
Study Director: Alfred Sommer, M.D. Johns Hopkins Bloomberg School of Public Health
Johns Hopkins Bloomberg School of Public Health
September 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP